GILD Price Prediction Next Week
Based on the provided data and technical analysis, here's the price prediction for GILD for the next trading week:
Technical Analysis
- RSI(14) at 57.33 indicates neutral momentum, not showing overbought or oversold conditions
- MACD at 0.36 shows slightly bullish momentum
- Price is trading above both SMA20 (91.99) and SMA60 (91.27), indicating an overall bullish trend
- Fibonacci levels suggest key resistance at 93.55 and support at 89.41
News Sentiment Analysis
- Recent positive catalysts include:
- Morgan Stanley's upgrade to Overweight
- Strong performance with 26.8% stock gain over past six months
- Successful approval of Livdelzi strengthening liver disease portfolio
Challenges
- Setbacks in oncology portfolio with Trodelvy trial failures
- Increased insider selling activity, including significant sale by CMO
- Cell Therapy franchise under competitive pressure
Price Target Prediction for Next Week
Base case: $92.50-93.50 (60% probability)
- Trading range between Fibonacci R1-R2 levels
- Supported by positive analyst sentiment and technical trend
Bullish case: $94.50-95.50 (25% probability)
- Break above R2 level if broader market sentiment improves
- Catalyst from potential EU approval of seladelpar in Q1
Bearish case: $89.00-90.00 (15% probability)
- Drop to S1 support level if market weakness persists
- Risk from competitive pressures in key segments
Trading Recommendation: HOLD Current price levels suggest limited upside in the short term. Better entry points may emerge on pullbacks to support levels around $89-90.
GILD Similar Chart Price Prediction
The price of GILD is predicted to go up 11.36%, based on the high correlation periods with SONY. The similarity of these two price pattern on the periods is 92.04%.
GILD
SONY
Up: 11.36%Similarity: 92.04%
GILD Revenue Forecast
GILD EPS Forecast
GILD FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
GILD VS S&P500
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Guidelines that aim to improve diagnosis and treatment rates, and new prophylaxis use, provide strong tailwinds for growth in HIV.
Gilead's pipeline could begin to see more blockbuster launches, particularly if Trodelvy is able to see solid data expanding its approved indication.
GILD Analyst's Forecast
Matthew Harrison
Morgan Stanley
Hold → Buy
Price Target
$87 → $113
Upside
+25.72%
Morgan Stanley upgraded Gilead to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for upward estimate revisions on lenacapavir forpre-exposure prophylaxis and further multiple expansion as the company makes progress with its next-gen HIV treatment strategy. The firm expects upward estimate revisions and further multiple expansion for Gilead. It sees "several key catalysts" for shares this year.
Tim Anderson
B of A Securities
Strong Buy
Price Target
$109
Upside
+18.04%
Brian Abrahams
RBC Capital
Hold
Price Target
$81 → $84
Upside
-5.04%